SONOSCAPE(SZ:300633) Huaan Securities·2025-08-26 10:53Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 964 million yuan in the first half of 2025, a year-on-year decline of 4.78%, and a net profit attributable to shareholders of 47 million yuan, down 72.43% year-on-year. The second quarter showed signs of improvement with a revenue of 534 million yuan, a year-on-year increase of 0.17% and a quarter-on-quarter increase of 24.24% [2][7] - The medical equipment industry is experiencing a recovery in terminal bidding and procurement activities, but the company faces short-term pressure due to high channel inventory accumulated over the past two years. It is expected that performance will improve in the second half of the year as channel inventory is digested [6][9] Financial Performance Summary - In the first half of 2025, the ultrasound segment generated revenue of 550 million yuan, down 9.87% year-on-year, while the endoscope and related consumables segment remained stable with revenue of 388 million yuan. Domestic revenue was approximately 495 million yuan, down 9.2% year-on-year, while overseas revenue was about 469 million yuan, up 0.3% year-on-year [6] - The company is increasing strategic investments, with sales, management, and R&D expense ratios at 31.63%, 7.11%, and 25.31% respectively, reflecting a year-on-year increase [7] - Revenue projections for 2025-2027 are expected to be 2.317 billion yuan, 2.765 billion yuan, and 3.203 billion yuan, with corresponding growth rates of 15.0%, 19.4%, and 15.9%. Net profit attributable to shareholders is projected to be 311 million yuan, 475 million yuan, and 614 million yuan for the same period, with growth rates of 118.5%, 52.7%, and 29.3% respectively [9][11]